DNA Sequencer for Shared Resource Lab

描述（由申请人提供）：本拨款申请申请购买应用生物系统3100基因分析仪的资金，以取代由维克森林大学医学院（WFUSM） DNA测序核心实验室操作的6年历史的应用生物系统377 DNA测序仪。现有的DNA测序仪为超过45项资助的NIH拨款提供支持。超过90%的WFUSM教师提交的样本是由NIH资助的。DNA测序实验室在方便的校园环境中为研究人员提供低成本，准确的测序技术。对自动DNA测序作为一种关键研究工具的需求稳步增长，并且随着2002年增加了多达10个教职岗位，预计未来两年服务需求将增加约25%。虽然目前的仪器表现良好，但平板凝胶技术正迅速被更灵敏、更高效的毛细管电泳所取代。测序技术的主要供应商应用生物系统公司决定停止使用377 DNA测序仪，这意味着目前使用的377 DNA测序仪将被淘汰。3100基因分析仪取代377将确保研究人员能够继续使用最新、最灵敏的测序技术，并使实验室能够向研究人员提供快速的测序数据。拟议的仪器将在服务收费的基础上提供给全体教员。在马克·莱弗利（Mark Lively）博士的指导和钟丽丝（Elyse Jung）女士的监督下，实验室以这种方式运作了六年。虽然仪器的大部分支持将来自用户费用，但额外的支持将由维克森林大学医学院综合癌症中心提供。高质量的仪器、经验丰富的人员和坚实的财政支持将确保美国国立卫生研究院资助的研究人员从拟议仪器的购买中受益。

DESCRIPTION (provided by applicant): This grant application requests funding for the purchase of an Applied Biosystems 3100 Genetic Analyzer to replace a six year old Applied Biosystems 377 DNA Sequencer that is operated by the DNA Sequencing Core lab of Wake Forest University School of Medicine (WFUSM). The existing DNA sequencer provides support for over 45 funded NIH grants. Over 90% of the samples submitted by WFUSM faculty are funded by NIH grant money. The DNA sequencing laboratory offers low cost, accurate sequencing technology to investigators in a convenient, on-campus setting. The demand for automated DNA sequencing as a critical research tool has grown steadily, and with the addition of up to ten faculty positions in 2002, an increased demand in services of about 25% over the next two years is anticipated. While the current instrumentation has performed well, slab gel technology is rapidly being replaced by more sensitive and efficient capillary electrophoresis. The decision by Applied Biosystems, the major supplier of sequencing technology, to discontinue the 377 DNA sequencer guarantees that the 377 DNA sequencer currently in use will become obsolete. Replacement of the 377 with the 3100 Genetic Analyzer will ensure that researchers have continued access to the most up-to-date, sensitive sequencing technology, and will allow the laboratory to provide rapid delivery of sequencing data to investigators. The proposed instrumentation will be available to the entire faculty on a fee-for-service basis. The lab has been operated in this way for six years, under the direction of Dr. Mark Lively and the supervision of Ms. Elyse Jung. While most of the support for the instrumentation will come from user fees, additional support will be provided by the Comprehensive Cancer Center of Wake Forest University School of Medicine. The combination of high quality instrumentation, experienced personnel, and solid financial support will ensure that NIH-funded researchers will benefit from acquisition of the proposed instrumentation.